BAY1082439

Modify Date: 2024-02-11 22:18:26

BAY1082439 Structure
BAY1082439 structure
Common Name BAY1082439
CAS Number 1375469-38-7 Molecular Weight 494.543
Density 1.4±0.1 g/cm3 Boiling Point N/A
Molecular Formula C25H30N6O5 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of BAY1082439


BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth[1][2].

 Names

Name bay-1082439
Synonym More Synonyms

 BAY1082439 Biological Activity

Description BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth[1][2].
Related Catalog
Target

PI3Kα

PI3Kβ

PI3Kδ

In Vitro BAY1082439 is a highly selective PI3Kα/α-balanced inhibitor. BAY1082439 has an IC50 ratio of 1:3 in biochemical assays of PI3Kα (4.9 nM) vs. PI3Kα (15.0 nM), and >1000-fold selectivity against mTOR kinase[1]. BAY1082439 (0.1-1 μM; 72 hours) is more effective than PI3Kα- and/or PI3Kβ-selective inhibitors in blocking PTEN-null prostate cancer cells[2]. Cell Viability Assay[2] Cell Line: PC3 and LNCaP cells (PTEN-null human prostate cancer cell lines) Concentration: 0.1, 0.33, 1, 3.3, 10 μM Incubation Time: 72 hours Result: Efectively inhibited cell growth by blocking the G1/S cell cycle transition and by inducing apoptosis.
In Vivo BAY1082439 (75 mg/kg; p.o.; daily for 4 weeks) is effective in preventing Pten-null prostate cancer progression[2]. Animal Model: Pten conditional knockout mouse model (Pb-Cre+;PtenL/L, CP model)[2] Dosage: 75 mg/kg Administration: P.o.; daily for 4 weeks Result: Significantly decreased tumor size and P-AKT staining, nearly normal luminal architecture, and a significant reduction of Ki67-positive cells. Significantly inhibit the human prostate cancer growth.
References

[1]. Ningshu Liu, et al. Abstract 2799: BAY 1082439, a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN. Abstract nr 2799. doi:1538-7445.AM2012-2799.

[2]. Yongkang Zou, et al. Co-Targeting the Cell Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ inhibitor BAY1082439. Mol Cancer Ther. 2018 Oct;17(10):2091-2099.

 Chemical & Physical Properties

Density 1.4±0.1 g/cm3
Molecular Formula C25H30N6O5
Molecular Weight 494.543
Exact Mass 494.227783
LogP -0.20
Index of Refraction 1.683

 Synonyms

bay-1082439
bay 2439
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here



Get all suppliers and price by the below link:

BAY1082439 suppliers

BAY1082439 price